A concise review of magnetic resonance molecular imaging of tumor angiogenesis by targeting integrin αvβ3 with magnetic probes

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1083-1093

  Liu, Yajie ^a   Yang, Yi ^a   Zhang, Chunfu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Integrin v 3; Molecular imaging; MRI; Paramagnetic liposome; Super paramagnetic iron oxide particles; Tumor angiogenesis

Indexed keywords

GADOLINIUM; PENTETIC ACID; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TETRAXETAN; VITRONECTIN RECEPTOR;

BASEMENT MEMBRANE; CARCINOGENESIS; CELL ACTIVATION; CELL PROLIFERATION; CYSTOSCOPY; DIFFUSION WEIGHTED IMAGING; ECHOGRAPHY; ENDOTHELIUM CELL; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; HUMAN; IONIZING RADIATION; MOLECULAR IMAGING; MOLECULAR PROBE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITRON EMISSION TOMOGRAPHY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RADIOFREQUENCY; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSMISSION ELECTRON MICROSCOPY;

INTEGRIN ΑVΒ3; MOLECULAR IMAGING; MRI; PARAMAGNETIC LIPOSOME; SUPERPARAMAGNETIC IRON OXIDE PARTICLES; TUMOR ANGIOGENESIS;

ANIMALS; HUMANS; INTEGRIN ALPHAVBETA3; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MOLECULAR IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84875208695     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S39880     Document Type: Review

References (71)

1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6(4):389-395.
2. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumours. Ann Surg. 1972;175(3):409-416.
3. Weidner N, Semple J P, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1-8.
4. Chiang AC, Massaqué J. Molecular basis of metastasis. N Engl J Med. 2008;359(26):2814-2823.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
6. Hagedorn M, Bikfalvi A. Target molecules for anti-angiogenic therapy: from basic research to clinical trials. Crit Rev Oncol Hematol. 2000;34(2):89-110.
7. Folkman J, Klagsbrun M. Angiogenic factors. Science. 2001; 235(4787):442-447.
8. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005;9(2):267-285.
9. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407(6801):242-248.
10. Nussenbaum F, Herman IM. Tumor angiogenesis: insights and innovations. J Oncol. 2010;2010:132641.
11. Auguste P, Lemiere S, Larrieu-Lahargue F, Bikfalvi A. Molecular mechanisms of tumor vascularization. Crit Rev Oncol Hematol. 2005;54(1):53-61.
12. Ramjaun AR, Hodivala-Dilke K. The role of cell adhesion pathways in angiogenesis. Int J Biochem Cell Biol. 2009;41(3):521-530.
13. Francavilla C, Maddaluno L, Cavallaro U. The functional role of cell adhesion molecules in tumor angiogenesis. Semin Cancer Biol. 2009;19(5):298-309.
14. Snoeks TJ, Löwik C W, Kaijzel EL. 'In vivo' optical approaches to angiogenesis imaging. Angiogenesis. 2010;13(2):135-147.
15. Mahmoudi M, Serpooshan V, Laurent S. Engineered nanoparticles for biomolecular imaging. Nanoscale. 2011;3(8):3007-3026.
16. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697-715.
17. Cai W, Sam Gambhir S, Chen X. Multimodality tumor imaging targeting integrin alphavbeta3. Biotechniques. 2005;39(SUPPL. 6): S14-S25.
18. Liu S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3) -targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem. 2009;20(12):2199-2213.
19. Danhier F, Le Breton A, Préat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm. 2012;9(11):2961-2973.
20. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2(2):91-100.
21. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264(5158):569-571.
22. Gladson CL. Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol. 1996; 55(11):1143-1149.
23. Liu Z, Peng R. Inorganic nanomaterials for tumor angiogenesis imaging. Eur J Nucl Med Mol Imaging. 2010;37 SUPPL. 1:S147-S163.
24. Zhang Y, Yang Y, Cai W. Multimodality imaging of integrin α(v)β(3) expression. Theranostics. 2011;1:135-148.
25. Beer AJ, Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev. 2008;27(4):631-644.
26. Contag CH. In vivo pathology: seeing with molecular specificity and cellular resolution in the living body. Annu Rev Pathol. 2007;2: 277-305.
27. Kim HL. Optical imaging in oncology. Urol Oncol. 2009;27(3): 298-300.
28. Deshpande N, Pysz MA, Willmann JK. Molecular ultrasound assessment of tumor angiogenesis. Angiogenesis. 2010;13(2):175-188.
29. Kobayashi H, Longmire MR, Ogawa M, Choyke PL. Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chem Soc Rev. 2011;40(9):4626-4648.
30. Kwee TC, Takahara T, Ochiai R, et al. Whole-body diffusion-weighted magnetic resonance imaging. Eur J Radiol. 2009;70(3):409-417.
31. Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metasta-ses in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging. 2009;30(2):298-308.
32. Tsushima Y, Takano A, Taketomi-Takahashi A, Endo K. Body diffusion-weighted MR imaging using high b-value for malignant tumor screening: usefulness and necessity of referring to T2-weighted images and creating fusion images. Acad Radiol. 2007;14(6):643-650.
33. He Q, Xu RZ, Shkarin P, et al. Magnetic resonance spectroscopic imaging of tumor metabolic markers for cancer diagnosis, metabolic phenotyping, and characterization of tumor microenvironment. Dis Markers. 2004;19(2-3):69-94.
34. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99(9):2293-2352.
35. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998;4(5):623-626.
36. Lanza GM, Winter PM, Caruthers SD, et al. Nanomedicine opportunities for cardiovascular disease with perfuorocarbon nanoparticles. Nanomedicine (Lond). 2006;1(3):321-329.
37. Winter PM, Caruthers SD, Kassner A, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu) beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 2003;63(18):5838-5843.
38. Schmieder AH, Winter PM, Caruthers SD, et al. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med. 2005;53(3):621-627.
39. Mulder WJ, Strijkers GJ, van Tilborg GA, Griffoen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed. 2006;19(1):142-164.
40. Morawski AM, Winter PM, Crowder KC, et al. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med. 2004;51(3):480-486.
41. Strijkers GJ, Kluza E, Van Tilborg GA, et al. Paramagnetic and fuo-rescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis. 2010;13(2):161-173.
42. Mulder WJ, Strijkers GJ, Habets J W, et al. MR molecular imaging and fuorescence microscopy for identifcation of activated tumor endothe-lium using a bimodal lipidic nanoparticle. FASEB J. 2005;19(14): 2008-2010.
43. Mulder WJ, van der Schaft DW, Hautvast PA, et al. Early in vivo assessment of angiostatic therapy effcacy by molecular MRI. FASEB J. 2007;21(2):378-383.
44. Gianella A, Read JC, Cormode D P, Fayad ZA, Mulder WJM. Multifunctional nanoparticles for target-specific imaging and therapy. In: Svenson S, Prud'homme K, editors. Multifunctional Nanoparticles for Drug Delivery Applications. New York: Springer. 2012:155-171.
45. Chen W, Jarzyna PA, van Tilborg GA, et al. RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J. 2010;24(6):1689-1699.
46. Tan M, Lu ZR. Integrin targeted MR imaging. Theranostics. 2011;1: 83-101.
47. Tassa C, Shaw S Y, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res. 2011;44(10):842-852.
48. Weinstein JS, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system infammatory pathologies, a review. J Cereb Blood Flow Metab. 2010;30(1):15-35.
49. Zhang C, Jugold M, Woenne EC, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007;67(4):1555-1562.
50. Jiang T, Zhang C, Zheng X, et al. Noninvasively characterizing the different alphavbeta3 expression patterns in lung cancers with RGD-USPIO using a clinical 3.0T MR scanner. Int J Nanomedicine. 2009;4:241-249.
51. Sjögren CE, Johansson C, Naevestad A, Sontum PC, Briley-Saebø K, Fahlvik AK. Crystal size and properties of superparamagnetic iron oxide (SPIO) particles. Magn Reson Imaging. 1997;15(1):55-67.
52. Ho D, Sun X, Sun S. Monodisperse magnetic nanoparticles for thera-nostic applications. Acc Chem Res. 2011;44(10):875-882.
53. Jeong U, Teng X, Wang Y, Yang H, Xia Y. Superparamagnetic colloids: controlled synthesis and niche application. Advanced Materials. 2007; 19(1):33-60.
54. Xu F, Lei D, Du X, Zhang C, Xie X, Yin D. Modifcation of MR molecular imaging probes with cysteine-terminated peptides and their potential for in vivo tumour detection. Contrast Media Mol Imaging. 2011;6(1):46-54.
55. Huang G, Zhang C, Li S, et al. A novel strategy for surface modifcation of superparamagnetic iron oxide nanoparticles for lung cancer imaging. J Mater Chem. 2009;19:6367-6372.
56. Xie X, Zhang C. Controllable assembly of hydrophobic superparamag-netic iron oxide nanoparticle with mPEG-PLA copolymer and its effect on MR transverse relaxation rate. J Nanomater. 2010;2011:Article ID 152524.
57. Xu F, Cheng C, Xu F, et al. Superparamagnetic magnetite nanocrystal clusters: a sensitive tool for MR cellular imaging. Nanotechnology. 2009;20(40):405102.
58. Wang Y, Xu F, Zhang C, et al. High MR sensitive fuorescent magnetite nanocluster for stem cell tracking in ischemic mouse brain. Nanomedicine: Nanotechnology, Biology, and Medicine. 2011;7(6): 1009-1019.
59. Zhang C, Xie X, Liang S, Li M, Liu Y, Gu H. Mono-dispersed high magnetic resonance sensitive magnetite nanocluster probe for detection of nascent tumor by magnetic resonance molecular imaging. Nanomedicine: Nanotechnology, Biology, and Medicine. 2012;8(6): 996-1006.
60. Nasongkla N, Bey E, Ren J, et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 2006;6(11):2427-2430.
61. Ai H, Flask C, Weinberg B, et al. Magnetite-loaded polymeric micelles as ultrasensitive magnetic-resonance probes. Advanced Materials. 2005;17(16):1949-1952.
62. Khemtong C, Kessinger C W, Ren J, et al. In vivo off-resonance saturation magnetic resonance imaging of alphavbeta3-targeted superpara-magnetic nanoparticles. Cancer Res. 2009;69(4):1651-1658.
63. Kluza E, van der Schaft DW, Hautvast PA, et al. Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett. 2010;10(1):52-58.
64. Kluza E, Jacobs I, Hectors SJ, et al. Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fuorescent liposomes to tumor endothelium in vivo. J Control Release. 2012;158(2):207-214.
65. Kiessling F, Huppert J, Zhang C, et al. RGD-labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Radiology. 2009;253(2):462-469.
66. Kircher M F, Willmann JK. Molecular body imaging: MR imaging, CT, and US. part I. principles. Radiology. 2012;263(3):633-643.
67. Kircher M F, Willmann JK. Molecular body imaging: MR imaging, CT, and US. Part II. Applications. Radiology. 2012;264(2):349-368.
68. Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008;14(4):459-465.
69. Wehrl H F, Sauter AW, Judenhofer MS, Pichler BJ. Combined PET/ MR imaging - technology and applications. Technol Cancer Res Treat. 2010;9(1):5-20.
70. Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53(6):845-855.
71. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008;452(7187):580-589.